Relationship between N-acetyl transferase-2 gene polymorphism and risk of bronchial asthma

Tuberkuloz ve Toraks

Volumn 54, Issue 2, 2006, Pages 137-143

  Tamer, Lülüfer ^a   Çalikoǧlu, Mukadder ^a   Aras Ateş, Nurcan ^a   Yildirim, Hatice ^a   Karakaş, Sevim ^a   Atik, Uǧur ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Asthma; NAT2; Polymorphism

Indexed keywords

ACYLTRANSFERASE;

ACETYLATOR PHENOTYPE; ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NAT2 GENE; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

ACETYLTRANSFERASES; ASTHMA; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RISK FACTORS; TURKEY;

EID: 33747071429     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 371: 25-79.
2. Hein DW, Ferguson RJ, Doll MA, et al. Molecular genetics of human polymorphic N-acetyltransferase: Enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric HAT2 allozymes. Hum Mol Genet 1994; 35: 729-34.
3. Rodriquez JW, Kirlin WG, Ferguson VJ, et al. Human acetylatorgenotype: Relationship to colorectal cancer incidence and arylamine N- acetyltransferase expression in colon cytosol. Arch Toxicol 1993; 67: 445-52.
4. Von Schmiedeberg S, Fritsche E, Ronnau AC, et al. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 1999; 455: 147-52.
5. May DG, Black CM, Olsen NJ, et al. Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin. Clin Pharmacol Ther 1990; 48: 286-95.
6. Kawakubo Y, Merk HF, Masaoudi TA, et al. N-acetylation of paraphenylenediamine in human skin and keratinocytes. J Pharmacol Exp Ther 2000; 292: 150-5.
7. Hacak M, Aynacioglu AS, Filiz A, et al. Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol 2002; 546: 671-4.
8. Ivaschenko TE, Sideleva OG, Baranov VS. Glutathione-S-transferase micro and theta gene polymorphisms as new risk factors ofatopic bronchial asthma. J Mol Med 2002; 80: 39-43.
9. American Thoracic Society. Standards for diagnosis of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-44.
10. Raunio H, Husgafvel-Pursiainen K, Anttila S, et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review. Gene 1995; 159: 113-21.
11. Kadlubar FF, Butler MA, Kaderlik KR, et al. Polymorphisms for aromatic amine metabolism in humans: Relevance for human carcinogenesis. Environ Health Perspect 1992; 98: 69-74.
12. Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): The identification of two novel allelic variants. Biochem Pharmacol 1988; 1: 361-6.
13. Griem P, Wulferink M, Sachs B, et al. Allergic and autoimmune reactions to xenobiotics: How do they arise? Immunol Today 1998; 193: 133-41.
14. Vavilin VA, Makarova SI, Liakhovich W, et al. Polymorphic genes of xenobiotic-metabolizing enzymes associated with bronchial asthma in genetically predisposed children. Genetika 2002; 384: 539-45.
15. Wikman H, Piirila P, Rosenberg C, et al. N-acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk. Pharmacogenetics 2002; 123: 227-33.
16. Luszawska-Kutrzeba T. NAT2* genotype in children with bronchial asthma and other atopic diseases. Ann Acad Med Stetin 1999; 45: 109-21.
17. Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G. Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 1999; 655: 562-9.
18. Zielinska E, Niewiarowski W, Bodalski J, et al. Arylamine N-acetyltransferase NAT2 gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997; 626: 635-42.
19. Orzechowska-Juzwenko K, Milejski P, Patkowski J, et al. Acetylator phenotype in patients with allergic diseases and its clinical significance. Int J Clin Pharmacol Ther Toxicol 1990; 2810: 420-5.
20. Stanley LA, Copp AJ, Pope J, et al. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology 1998; 585: 174-182.